Tiger Brokers

Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)

Reuters
Mar 27
<a href="https://laohu8.com/S/PVLA">Palvella Therapeutics</a> announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)
  • Palvella reported that it will present two posters at the 2026 American Academy of Dermatology Annual Meeting, including data on QTORIN rapamycin topical formulation work and an interview study on porokeratosis burden.
  • In the QTORIN rapamycin poster, the company described its Phase 3 SELVA study in microcystic lymphatic malformations as having met the primary endpoint on mLM-IGA (p<0.001) and reported rapamycin systemic levels below 2 ng/mL at all measured timepoints.
  • The porokeratosis poster summarizes 10 qualitative interviews conducted with patients (n=9) and a caregiver (n=1) to assess physical, psychosocial, cancer-related, and treatment burdens.
  • Palvella said it plans to start a Phase 2 trial of QTORIN pitavastatin for disseminated superficial actinic porokeratosis in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271030PRIMZONEFULLFEED9679571) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10